Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:48:26.989Z.
Calculation as of: 2026-10-06T21:48:26.989Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d5cf33dffe9efe5aedd0b9249044aa6ff6bda4d300b25a987f268f0e56c28a6c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Taysha Gene Therapies, Inc.
Market Cap
$1.40B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.42B
EV/EBITDA Ratio
11.44x
TTM Avg
34.83x
3Y Avg
34.83x
5Y Avg
32.76x
Market Cap
$1.39B
EV/EBITDA Ratio
25.34x
TTM Avg
25.42x
3Y Avg
27.51x
5Y Avg
46.70x
Market Cap
$1.42B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.45B
EV/EBITDA Ratio
8.94x
TTM Avg
18.38x
3Y Avg
16.03x
5Y Avg
16.85x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | $1.40B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 11.44x | 34.83x | 34.83x | 32.76x |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 25.34x | 25.42x | 27.51x | 46.70x |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.44B | 26.24x | 16.63x | 66.61x | 73.09x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 8.94x | 18.38x | 16.03x | 16.85x |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | N/A | 5.67x | 5.67x | 5.67x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
